Concepedia

Michael A. Clegg

MA

Statistics

Publications

3

Citations

158

H-Index

3

Active since

2016

Affiliations

GlaxoSmithKline (United Kingdom)(Current)

University of Strathclyde

Michael A. Clegg is an author at GlaxoSmithKline (United Kingdom) specializing in bromodomain inhibition, ligand binding, and enzyme inhibition.

Publications per year

2016–2021

3

Publications

3

Diamond-coated ‘black silicon’ as a promising material for high-surface-area electrochemical electrodes and antibacterial surfaces

Paul May, Michael A. Clegg, Tiago Almeida Silva et al. · Journal of Materials Chemistry B · 2016 · 108 citations · Full text

, , +17

Application of Atypical Acetyl-lysine Methyl Mimetics in the Development of Selective Inhibitors of the Bromodomain-Containing Protein 7 (BRD7)/Bromodomain-Containing Protein 9 (BRD9) Bromodomains

Michael A. Clegg, Paul Bamborough, Chun‐wa Chung et al. · Journal of Medicinal Chemistry · 2020 · 36 citations · Full text

, , +13

Optimization of Naphthyridones into Selective TATA-Binding Protein Associated Factor 1 (TAF1) Bromodomain Inhibitors

Michael A. Clegg, Natalie H. Theodoulou, Paul Bamborough et al. · ACS Medicinal Chemistry Letters · 2021 · 14 citations · Full text

, , +15

1–3 of 3